InsiderTrades

Form 4 for BAX Baxter International

Accepted 2025-09-04 00:00:00 ET · period of report 2025-09-02 · accession 0001940945-25-000008 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DM 2025-09-04 2025-09-02 BAX Hider Andrew P. Pres, CEO, Dir A - Grant $0.00 +368.1K 368.1K New $0
D 2025-09-04 2025-09-02 BAX Hider Andrew P. Pres, CEO, Dir A - Grant $0.00 +465.7K 465.7K New $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock, $1 par value 2025-09-02 A A 236,237 $0.00 236,237 D — — (F1) The reporting person received a grant of restricted stock units (RSUs) as compensation for the unvested portion of certain equity awards previously granted by the reporting person's prior employer (the Make Whole Award). The Make Whole Award is scheduled to vest in three equal annual installments beginning on September 2, 2026, the first anniversary of the grant date, subject to satisfaction of the related vesting requirements set forth in the Baxter International Inc. (Baxter) 2021 Amended and Restated Incentive Plan (the Plan). Any outstanding and unvested portion of the Make Whole Award will immediately vest if the reporting person's employment is terminated by Baxter other than for Cause (as defined in Baxter's Executive Severance Plan) or by the reporting person for Good Reason (as defined in the Offer Letter, effective as of July 7, 2025, by and between the reporting person and Baxter).
2 Common Common Stock, $1 par value 2025-09-02 A A 131,813 $0.00 368,050 D — — (F2) The reporting person received RSUs as a pro rata grant under Baxter's 2025 annual equity incentive compensation program that are scheduled to vest in three equal annual installments beginning on September 2, 2026, the first anniversary of the grant date, subject to satisfaction of the related vesting requirements set forth in the Plan.
3 Derivative Stock Option (Right to Buy) 2025-09-02 A A 465,651 $0.00 465,651 D $24.17 · — to 2035-09-02 465,651 Common Stock, $1 par value (F3) The reporting person received stock options as a pro rata grant under Baxter's 2025 annual equity incentive compensation program, with such options becoming exercisable in three equal annual installments beginning on September 2, 2026, the first anniversary of the grant date, subject to the terms of the Plan.